Novartis won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drugmaker’s top-selling multiple sclerosis medicine Gilenya in the United States, at least until a patent dispute is resolved.
In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.
Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.
New Zealand medical device maker Fisher & Paykel Healthcare Corp. Ltd. and U.S. rival ResMed Inc. agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees.
Edwards Lifesciences Corp. paid rival Boston Scientific Corp. $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.